$LEGN

Casey Patrick John sold $89K of LEGN

Casey Patrick John sold 6,000 shares of Legend Biotech Corp (LEGN) at $14.80 on 2026-06-30.

Original reporting
SEC EDGAR · Casey Patrick John
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LEGN
Neutral
medium confidence
Mentioned
$LEGN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNNeutralLow
01

Why it matters

The disclosure indicates an open-market sale of 6,000 shares at $14.80 on June 30, with holdings after the transaction of 48,604 shares.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new operational or financial catalyst.

03

What to watch

The article provides only the sale size and post-transaction holdings, not total insider ownership changes, sale history, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: Form 4 filed July 2, covering a June 30 sale.

Background

This is an SEC Form 4 insider transaction disclosure for Legend Biotech director Casey Patrick John.

Company-level read

Ticker impact

$LEGNNeutralMedium confidence
Context

Legend Biotech director Casey Patrick John sold 6,000 shares in an open-market transaction for about $88.8K, per Form 4 filed July 2.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing discloses a small-to-moderate dollar value sale by a director, with no accompanying company-specific catalyst (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; this is company-specific insider transaction data, not a sector-wide signal.

None.

None.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Legend Biotech Corp

    Company whose director insider sale is disclosed on Form 4.

  • Casey Patrick John

    Director who sold 6,000 shares in an open-market transaction.

Related articles

$LEGNMed

LEGN Stock Drops As UBS Slashes Price Target On Carvykti Fears

Legend Biotech (NASDAQ: LEGN) shares fell about 14% on July 27, after UBS cut its rating to Neutral and lowered its price target to $28 from $49. The move reflects concerns about Carvykti growth amid rising competition from other multiple myeloma therapies. LEGN traded from about $30 in early July to about $19 by July 27.

$LEGNMed

LEGN Stock Slumps As UBS Slashes Price Target On Carvykti Concerns

Legend Biotech (NASDAQ: LEGN) shares fell about 14% after UBS cut its rating to Neutral from Buy and lowered its Carvykti-related price target to $28 from $49. UBS cited weaker-than-expected Carvykti growth, a smaller market opportunity, and increased competition. The stock dropped from around $30 in early July to about $19 by July 27.

$LEGNMedAI 8/10

Legend Biotech Stock Falls 15% Over CEO Transition

Legend Biotech (LEGN) shares fell about 15% after CEO Ying Huang stepped down effective July 24, 2026. The stock dropped 15.30% to $18.82 on the Nasdaq from $22.22. The board named Alan Bash, president of the CARVYKTI business unit, interim CEO and started a search for a permanent replacement.